• Explore /
  • Poster
  • / Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.

Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.

Abstract Poster

Authors

null

David Planchard

Gustave Roussy, Villejuif, France

David Planchard , Benjamin Besse , Tae Min Kim , Elisabeth A. Quoix , Pierre Jean Souquet , Julien Mazieres , Fabrice Barlesi , Harry J.M. Groen , Egbert F. Smit , Christina S. Baik , Byoung Chul Cho , Ronan Joseph Kelly , Mark A. Socinski , Silvia Novello , James R. Rigas , Vanessa Giannone , Anthony Michael D'amelio Jr., Pingkuan Zhang , Bijoyesh Mookerjee , Bruce E. Johnson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01336634

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9075)

DOI

10.1200/JCO.2017.35.15_suppl.9075

Abstract #

9075

Poster Bd #

401

Abstract Disclosures

Similar Posters

First Author: Gregory J. Riely

First Author: Peter H. O'Donnell

First Author: Se-Hoon Lee

First Author: Makoto Tahara